SupremeCourt

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Friday, February 15, 2013

The ‘Global’ Fund being criticized

Posted on 8:10 PM by Unknown
The Global Fund to fight AIDS, Tuberculosis and Malaria was created in 2002 in order to attract, manage and disburse resources to fight these three deadly diseases across the world. Since its inception, as reported, the Global Fund has supported more than 1,000 programs in 151 countries, providing AIDS treatment for 4.2 million people, anti-tuberculosis treatment for 9.7 million people and 310 million insecticide-treated nets for the prevention of malaria. It has also become the main multilateral funder in global health. In this regard, as reported, the Fund channels 82% of the international financing for TB, 50% for malaria, and 21% of the international financing against AIDS. 

The Global Fund has an international Board which includes representatives of donor and recipient governments, non-governmental organizations, the private sector and affected communities. It relies on voluntary funding from all sectors- private, government, social enterprises, philanthropic foundations and individuals. The Global Fund does not implement programs directly but selects Local Funds Agents to verify, oversee and report grant performances in countries where grants have been made. For more about the Global Fund read here. Image from here.

Recently, the Global Fund has come to be criticized by United States Senator Orrin Hatch (Republican) for its policy promoting procurement of generic drugs and compulsory licensing. Though Mr. Hatch is now opposing generic drugs for other countries, it is important to note that he was a co-sponsor to the United States Hatch-Waxman Act of 1984 which encouraged generic drugs! What could be the reason for such double standards? 

As reported, Senator Hatch wrote a letter in April 2011 to the then Sectary of State Hillary Clinton attacking the Global Fund’s strategy of training public health officials of developing countries to make use of TRIPS flexibilities in order to ensure access to medicine. In the letter it was claimed that the Global Fund paid more for generic drugs than for brand name versions thereby “making inefficient and unnecessarily costly procurement decisions that come with dire consequences.” 

The letter also made references to slides that were used by the Global Fund to brief officials on how to use compulsory licensing. As reported, Mr. Hatch said “by advocating for developing countries to disregard the TRIPS through issuing compulsory licenses to gain access to Global Fund grants, we are abusing the system”. These concerns are misplaced because the TRIPS in itself provides for compulsory licensing as a way to make medicines more affordable in times of need and countries are permitted to decide for themselves when to issue such licenses. In any case, a compulsory license can be issued only under certain circumstances and not in any and every situation. Mr. Hatch then requested Secretary Clinton to “provide an immediate plan of action prohibiting any seminars or working groups by the Global Fund relating to educating, training and advocating for countries to issue compulsory licenses.” Is this sheer insecurity? Can educating developing nations about options legitimately available to them be an ‘illegal’ act requiring prohibition? 

Another development which may have implications on the policy of the Global Fund, as reported, is the change in the Fund’s management. Ambassador Mark Dybul, a former US Global AIDS Coordinator, is the new head of the organization. Dybul was known for his role in creating the US-based President’s Emergency Program for AIDS Relief (PEPFAR). This legislation also came under attack in the letter where Mr. Hatch was dismayed at how the legislation promotes use and purchase of generics (read here). Interestingly, more changes were in store for the Fund. In November 2011, Christopher Game was appointed as the new Procurement Officer. It is pertinent to note that Mr. Game worked extensively with Abbott and Novartis. Abbott is a private sector contributor to the Fund and it is speculated that this change came as result of Abbott’s and Senator Hatch’s lobbying efforts against the procurement of generic drugs. 

These claims and changes come at a time when ‘totally drug restraint’ tuberculosis is spreading in South Africa (read here). Researches warn that if such outbreaks are not addressed this strain of tuberculosis could consume populations and economies. People fear a repeat of the 1980 breakout in New York which killed 90% of the patients who contracted the TB strain. Though factors driving the drug restraint TB are not yet understood, researchers are advocating screening tests in order to isolate patients suffering from the ‘virtually untreatable strain of TB’. 

Given the dominant US based leadership of the ‘Global’ Fund, it remains to be seen as to how the Fund will respond to the TB crisis in South Africa and to its procurement and IPR policy.
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Posted in access, Compulsory Licensing, Generic medicine | No comments
Newer Post Older Post Home

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • IPAB on Payyannur Ring
    [*S lightly long post] Background: The Intellectual Property Appellate Board (“ IPAB ”), in its recent order in SubhashJewellery v. Payyan...
  • Guest Post: Intermediary liability in defamation cases - Parle, Mouthshut & Visakha cases to clarify the law
    Chaitanya Ramachandran, who has blogged for us previously over here and here , has sent us this excellent guest post analyzing the extent of...
  • Delhi HC rejects the "Hot News" Doctrine: A Summary
    The applicability of the Hot News doctrine was rejected recently in a landmark ruling delivered by Justice Bhat of the Delhi HC. This post i...
  • IP Research Assistant position at IIT, Madras
    Feroz Ali Khader, MHRD IP Chair at the Indian Institute of Technology (IIT) Madras, is looking for research assistants to work on various is...
  • Satyajit Ray's sketches and copyright controversies
    A copyright row appears to have started between the Satyajit Ray Society and the Delhi Art Gallery, that is organising a countrywide exhibit...
  • Dorling Kindersley v. Sanguine Technical Publishers
    A recent Delhi High Court order passed on 21 January, 2013  with respect to copyright licensing has come to our notice. An analysis of the j...
  • Call for Papers: IIT Bombay and MHRD jointly announce the 2nd International Conference on Management of Intellectual Property and Strategy
    The readers may be interested to know that the Shailesh J. Mehta School of Management of IIT Bombay is geared up to host, in collaboration w...
  • SpicyIP Tidbit: ALCS August Distribution
    In the UK, the Authors' Licensing and Collecting Society is an organization run and owned by writers that collects money due to its mem...
  • Aaron Swartz, RIP
    See Cory Doctorow's eulogy here Some of us in India may not have heard of Aaron Swartz, a 26 year old activist who was heavily involved ...
  • Thalappakatti biryani trademark row
    The southern district of Dindigal in Tamil Nadu occupies a special place in the hearts of biryani lovers. In the late 1950s, one Nagasamy N...

Categories

  • 126 (1)
  • 3(d) (4)
  • 3(f) (1)
  • 3(i) (1)
  • 3(k) (2)
  • Academic Writing (1)
  • access (10)
  • access to food (1)
  • access to health (3)
  • AIA (1)
  • AIDS/HIV (3)
  • Antitrust (2)
  • Bajaj v LML (1)
  • Basmati Row (2)
  • Biological Diversity (5)
  • Biologics (2)
  • biopiracy (4)
  • biotech (7)
  • Bollywood (25)
  • Broadcasters Rights (5)
  • Budget (1)
  • business method patent (2)
  • Call for papers (2)
  • Cipla (2)
  • Comparative Advertising (4)
  • Competition law (8)
  • Compulsory Licensing (27)
  • condonation of delay (1)
  • Conference (4)
  • Constitution (12)
  • Contracts (1)
  • Controller's decisions (8)
  • Copyright (112)
  • Copyright Amendment Bill 2010 (23)
  • copyright board (4)
  • Copyright Exceptions (6)
  • copyright office (1)
  • Copyright Rules (2013) (5)
  • Copyright Societies (9)
  • Counterfeiting (1)
  • creativity (1)
  • Cross Retaliation (1)
  • csir (4)
  • d (1)
  • D.U. Photocopy Case (16)
  • Darjeeling Tea (3)
  • Data Exclusivity (2)
  • Database (1)
  • DCGI (2)
  • decompilation (2)
  • defamation (9)
  • Designs (3)
  • Designs Act (3)
  • Differential Pricing (2)
  • Dilution (1)
  • Disabilities (3)
  • Disability (2)
  • DMCA (2)
  • Doha Declaration (1)
  • Domain Names (2)
  • Draft Policy of the Indian Government (2)
  • DRM (1)
  • Drug Regulation (7)
  • education (12)
  • Enercon (1)
  • Enforcement (1)
  • EU (2)
  • ex parte (2)
  • exhaustion (3)
  • Exhaustion of Rights (2)
  • Fair Dealing (8)
  • Fair Use (11)
  • Federal Circuit (1)
  • Fees (3)
  • FICCI (7)
  • FRAND (2)
  • free trade agreement (3)
  • FTA (3)
  • G.I. Registry (4)
  • gene sequences (3)
  • Generic medicine (4)
  • Geographical Indication (14)
  • Gilead (1)
  • Glenmark (5)
  • Gopika (34)
  • Guest post (11)
  • guidelines (1)
  • GWU-CII (1)
  • Herceptin (1)
  • hot news (3)
  • ICANN (1)
  • incremental innovation (1)
  • independence (1)
  • india (5)
  • Indian Government (1)
  • Indian patent litigation (27)
  • Indian Pharma (35)
  • Injunction (10)
  • Innovation (7)
  • INTA (1)
  • Intermediaries (10)
  • internet (11)
  • Internet Access Providers (IAPs) (5)
  • Internet Censorship (7)
  • IP scholarship (3)
  • IP aware (4)
  • IP Course (3)
  • IP Education (1)
  • IP Policy (11)
  • IP update (4)
  • ip writing competition (1)
  • IPAB (34)
  • ipchair (1)
  • IPO (1)
  • IPRS (5)
  • IT Act (1)
  • Journal (2)
  • judicial independence (3)
  • Jurisdiction (1)
  • Kruttika (4)
  • Legal Education (3)
  • Legal Research Tools (1)
  • Legal Scholarship (2)
  • library (2)
  • Licensing (7)
  • Madhulika (20)
  • mathematical methods (1)
  • Media law (3)
  • medical method (1)
  • Merck (4)
  • mhrd ip chair (1)
  • Microsoft (3)
  • Middle Path (1)
  • Moral Rights (2)
  • Movies (18)
  • musical work (2)
  • nanotechnology (1)
  • Natco (3)
  • natco defamation suit (5)
  • natco vs bayer (4)
  • need for transparency (1)
  • Novartis (8)
  • Novartis patent case in India (11)
  • NPEs (2)
  • nujs (1)
  • NUJS Conference (2)
  • Obituary (1)
  • obviousness (7)
  • Off-Topic (2)
  • online course (4)
  • Open Access (6)
  • Open Source (2)
  • Opposition (3)
  • Parallel Imports (4)
  • Parliament (1)
  • passing off (5)
  • Patent (52)
  • Patent act (10)
  • patent agent (5)
  • patent agent exam (9)
  • patent agent exam qualifications (3)
  • patent infringement (5)
  • Patent Licensing (2)
  • Patent litigation (2)
  • Patent Office (19)
  • patent pool (3)
  • Patent Prosecution (7)
  • Patent rules (2)
  • Patent Strategies (8)
  • Patents (9)
  • pegasus (1)
  • Personality Rights (1)
  • Pfizer (1)
  • Pharma (18)
  • Piracy (5)
  • plagiarism (3)
  • Plant Variety Protection (2)
  • post grant (1)
  • Prashant (2)
  • Preventive Detention (1)
  • Price Control (6)
  • prior publication (1)
  • Privacy (3)
  • Prizes (1)
  • public health (3)
  • Public Interest (4)
  • Publicity Rights (4)
  • Publishing (3)
  • radio (2)
  • Rajiv (18)
  • Rectification Petition (2)
  • Rejection (1)
  • research (3)
  • reverse engineering (2)
  • revocation (4)
  • rip (1)
  • Roche (2)
  • Roche vs Cipla (1)
  • Royalty (2)
  • RTI (2)
  • Scholarship (4)
  • section 16 (1)
  • Section 3(d) (7)
  • section 8 (6)
  • shamnad (11)
  • Shan Kohli (4)
  • Shouvik Kumar Guha (30)
  • Smartphones/Tablets (2)
  • Social Innovation (1)
  • Software (10)
  • software enforcement (3)
  • software patent (3)
  • Special 301 Report (1)
  • Spicy Tidbits (6)
  • spicyip (1)
  • SpicyIP Accolades (1)
  • SpicyIP Announcements (9)
  • SpicyIP Case (1)
  • SpicyIP Cases (3)
  • spicyip commiseration (1)
  • SpicyIP Events (11)
  • SpicyIP Fellowship (5)
  • SpicyIP Guest Series (22)
  • SpicyIP Interview (2)
  • SpicyIP Jobs (4)
  • SpicyIP Jobs/General (2)
  • SpicyIP Review (1)
  • SpicyIP Tidbits (11)
  • SpicyIP Weekly Review (27)
  • Statutory Licensing (1)
  • STI Policy 2013 (4)
  • Sugen (3)
  • Supreme Court of India (5)
  • Swaraj (19)
  • Tarnishment (1)
  • Technology (6)
  • Technology Transfer (5)
  • TKDL (5)
  • TPP (1)
  • trade (4)
  • Trade Secret Protection (1)
  • Trademark (59)
  • Trademark dilution (1)
  • Trademark Registry (9)
  • Traditional Knowledge (7)
  • Transparency (5)
  • treaty (1)
  • trial (1)
  • tribunals (2)
  • TRIPS (11)
  • UK (3)
  • unfair competition (5)
  • UNFCCC (1)
  • Universities Research and Innovation Bill (2)
  • US (1)
  • US Patent Reform (1)
  • US Supreme Court (3)
  • viva (3)
  • WIPO (5)
  • Working a Patent (2)
  • Workshop (4)
  • writ (1)
  • WTO (1)

Blog Archive

  • ▼  2013 (364)
    • ►  September (13)
    • ►  August (41)
    • ►  July (36)
    • ►  June (36)
    • ►  May (32)
    • ►  April (51)
    • ►  March (66)
    • ▼  February (40)
      • Off-Topic: Call for Papers from the Journal of Tel...
      • Budget 2013-14: What’s in stock for IP and innovat...
      • LDCs seek indefinite extension of transition perio...
      • Madras High Court judgment gives a boost to unauth...
      • SpicyIP Event: MIP India IP and Innovation Forum
      • National Innovation Foundation: Boosting Frugal Te...
      • SpicyIP Weekly Review (February Week 4)
      • SpicyIP Tidbit: Retraction Watch posts restored
      • Revisiting the Trans Pacific partnership agreement
      • The Sugen v. Cipla post-grant opposition: The lost...
      • Legality of trademark protection for deities in th...
      • Guest Post: The complex problem of developing mode...
      • SpicyIP Weekly Review- ( February Week 3)
      • Blocking (Counting) your Chickens before they hatc...
      • Accessibility of public libraries to persons with ...
      • The ‘Global’ Fund being criticized
      • Spicy IP Tidbit: Indian patent office puts an end ...
      • The G.I. Registry digitizes all G.I. records: Tran...
      • Dorling Kindersley v. Sanguine Technical Publishers
      • BMS Hepatitis Patent Invalidated: A Viral Effect f...
      • Patent prosecution highway: A potential game chang...
      • SpicyIP Event: Pharma IPR 2013
      • Patent Office finally takes Form 27s seriously
      • SpicyIP Weekly Review- (February Week 2)
      • Why aren’t there any takers for compulsory licenses?
      • The 19 year war- Financial Times Ltd. v Times Publ...
      • RetractionWatch fiasco: Manipulation of DMCA notic...
      • IPAB directs IPO to accept national phase patent a...
      • SpicyIP Events: MIP's 2nd Annual India IP and Inno...
      • New Unitary Patent System For Europe
      • Is there a need to break up the cartels in the rad...
      • Jailbreaking Sony Playstations To Be Illegal in In...
      • Is the suit again the Registrar of Copyright maint...
      • Déjà vu for Akhtar – nightmare before Barasat Cour...
      • Faking it! Indian Companies using IKEA’s trademarks
      • Latest In: Delhi HC bars Bisleri from using brand ...
      • Part II: Digitization- Growth trends of the Film a...
      • Part I: Digitization of content: a comparative ana...
      • Patent office notifies the next patent agent exami...
      • IPAB revokes several claims of yet another patent ...
    • ►  January (49)
  • ►  2012 (131)
    • ►  December (29)
    • ►  November (42)
    • ►  October (50)
    • ►  September (10)
Powered by Blogger.